TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15948237

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg/d for 6 months (group 1 and group 2)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg/d for 12 months (group 1 and group 2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no treatment, group 3 and group 4)
Number of subjects: 37
Study: 12725187

Group type: EXPERIMENTAL
Intervention: Blow oxygen method
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (only tube insertion)
Number of subjects: 28
Study: 9615374

Group type: EXPERIMENTAL
Intervention: Stroke patients
Number of subjects: 221

Group type: COMPARATOR
Intervention: Age- and sex-matched controls
Number of subjects: 221
Study: 8080893

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg orally three times a week, 25 mg twice a week for the first 2 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2676649

Group type: EXPERIMENTAL
Intervention: 10 mg ketorolac
Number of subjects: 115

Group type: COMPARATOR
Intervention: Doleron (two tablets: 150 mg dextropropoxyphene napsylate, 350 mg aspirin, 150 mg phenazone)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Doleron (two tablets)
Number of subjects: 115
Study: 861482

Group type: EXPERIMENTAL
Intervention: Graduated static compression stockings
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control leg (no stockings)
Number of subjects: 70
Study: 29650706

Group type: EXPERIMENTAL
Intervention: AD-HFpEF
Number of subjects: 0

Group type: COMPARATOR
Intervention: S-HFpEF
Number of subjects: 0
Study: 26323054

Group type: EXPERIMENTAL
Intervention: manual-guided cognitive behavioral therapy (CBT) for insomnia
Number of subjects: 66
Study: 25115308

Group type: EXPERIMENTAL
Intervention: Neck-specific training
Number of subjects: 144

Group type: COMPARATOR
Intervention: Prescribed physical activity
Number of subjects: 144
Study: 23423417

Group type: EXPERIMENTAL
Intervention: Measurement of procalcitonin to guide antibiotic prescriptions
Number of subjects: 0
Study: 19766209

Group type: EXPERIMENTAL
Intervention: Contraceptive pills and metformin
Number of subjects: 164
Study: 18537126

Group type: EXPERIMENTAL
Intervention: Cluster mean imputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple imputation (pooled across clusters)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard multiple imputation (not accounting for intracluster correlation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specialized multiple imputation (accounting for intracluster correlation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Within-cluster multiple imputation
Number of subjects: 0
Study: 15959425

Group type: EXPERIMENTAL
Intervention: Glimepiride 1 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glibenclamide 1.25 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study: 12919990

Group type: EXPERIMENTAL
Intervention: Intervention group with algorithm and instant camera for diagnosis
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control group (no algorithm or camera)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 468
Study: 10065089

Group type: EXPERIMENTAL
Intervention: HAI with MFFM (Mitoxantrone, Mitomycin C, 5-FU + FA)
Number of subjects: 222

Group type: COMPARATOR
Intervention: HAI with 5-FUDR
Number of subjects: 222

Group type: COMPARATOR
Intervention: Systemic chemotherapy with 5-FU + FA
Number of subjects: 222

Group type: COMPARATOR
Intervention: HAI with 5-FU + FA
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Secondary liver resection after HAI with MFFM
Number of subjects: 222
Study: 7546063

Group type: EXPERIMENTAL
Intervention: Partial coverage helmet
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Full coverage helmet
Number of subjects: 50

Group type: COMPARATOR
Intervention: No helmet
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All helmet conditions
Number of subjects: 50
Study: 1683183

Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6275468

Group type: EXPERIMENTAL
Intervention: Adjuvant cerebral irradiation (30 grays to the brain overall in 10 fractions over two weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (30 grays to the brain overall in 10 fractions over two weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Adjuvant cerebral irradiation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 30117164

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1,200 mg/day)
Number of subjects: 0
Study: 27761741

Group type: COMPARATOR
Intervention: bifrontal tDCS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: multisite treatment of bifrontal tDCS before bilateral auditory cortex tRNS
Number of subjects: 40
Study: 26116470

Group type: EXPERIMENTAL
Intervention: Dobutamine (DB) at stepwise doses of 5‐10‐15‐20 μg/kg/min
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 23357149

Group type: EXPERIMENTAL
Intervention: Specific Lp(a) apheresis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 30
Study: 21343239

Group type: EXPERIMENTAL
Intervention: RVP-max (maximal right ventricular pacing)
Number of subjects: 22

Group type: COMPARATOR
Intervention: RVP-min (minimal right ventricular pacing)
Number of subjects: 22
Study: 19757014

Group type: EXPERIMENTAL
Intervention: Neighborhood disadvantage, social support, negative affect/perceived stress
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Negative affect/perceived stress
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Policy, community, and individual-level interventions
Number of subjects: 399
Study: 17828086

Group type: EXPERIMENTAL
Intervention: Sinuforte monotherapy in a single daily dose for 7 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional treatment for 7 days
Number of subjects: 120
Study: 15173403

Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of energy) for 3 weeks
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Low-fat diet (29% of energy) for 3 weeks
Number of subjects: 2
Study: 10828731

Group type: EXPERIMENTAL
Intervention: 2 mg of nicotine polacrilex
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9115804

Group type: EXPERIMENTAL
Intervention: Dietary advice by practice nurses
Number of subjects: 956

Group type: COMPARATOR
Intervention: Usual care (standard health education materials)
Number of subjects: 956
Study: 8478502

Group type: EXPERIMENTAL
Intervention: Full-dose maintenance treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Half-dose maintenance treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full-dose vs Half-dose
Number of subjects: 0
Study: 3538178

Group type: EXPERIMENTAL
Intervention: Standard Care (SC)
Number of subjects: 10940

Group type: COMPARATOR
Intervention: Research Care (RC)
Number of subjects: 10940

Group type: EXPERIMENTAL
Intervention: Subgroup of persons with DBP 90 to 104 mm Hg
Number of subjects: 10940
Study: 31471827

Group type: EXPERIMENTAL
Intervention: Decoy option (two appointments: one with a male endoscopist and one with a female endoscopist)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Control (appointment with a female endoscopist)
Number of subjects: 602
Study: 30232974

Group type: EXPERIMENTAL
Intervention: Mobile phone-based short message services (SMSs) delivered for 12 months, tailored to recent FBG values.
Number of subjects: 955

Group type: COMPARATOR
Intervention: Control group (no SMS intervention).
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Intervention group compared to control group, adjusted for baseline FBG.
Number of subjects: 955
Study: 27711089

Group type: EXPERIMENTAL
Intervention: Combination of serenoa repens, selenium and lycopene extract + bromelain and methylsulfonylmethane extract with levofloxacin 500 mg o.d. for 14 days (Group A)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg o.d. for 14 days only (Group B)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combination of serenoa repens, selenium, lycopene + bromelain and methylsulfonylmethane extracts with levofloxacin (Group A)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Levofloxacin only (Group B)
Number of subjects: 79
Study: 24909532

Group type: EXPERIMENTAL
Intervention: Dyad practice
Number of subjects: 36

Group type: COMPARATOR
Intervention: Individual practice
Number of subjects: 36
Study: 22258155

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RST)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Physiotherapy (PT)
Number of subjects: 41
Study: 20146022

Group type: EXPERIMENTAL
Intervention: Perceived discrimination
Number of subjects: 36831
Study: 18981773

Group type: EXPERIMENTAL
Intervention: HIV-1 PCR testing at 4-8 weeks followed by a second test at 1 month after weaning or at 1 year of age
Number of subjects: 1609
Study: 16188750

Group type: EXPERIMENTAL
Intervention: Intervention group (four group sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 60
Study: 12431356

Group type: EXPERIMENTAL
Intervention: DTPw-HB/Hib pentavalent combination vaccine
Number of subjects: 207

Group type: COMPARATOR
Intervention: DTPw-HB vaccine alone
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: DTPw-HB/Hib pentavalent vaccine
Number of subjects: 207

Group type: COMPARATOR
Intervention: DTPw/Hib vaccine
Number of subjects: 207
Study: 9867443

Group type: EXPERIMENTAL
Intervention: GIK (glucose, insulin, and potassium infusion)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Control
Number of subjects: 407
Study: 7872278

Group type: EXPERIMENTAL
Intervention: 250 mg t.i.d. azithromycin, tetracycline 500 mg q.i.d., bismuth subsalicylate 2 tablets q.i.d.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 250 mg b.i.d. azithromycin, tetracycline 500 mg q.i.d., bismuth subsalicylate 2 tablets q.i.d.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 250 mg t.i.d. azithromycin, tetracycline 500 mg q.i.d., bismuth subsalicylate 2 tablets q.i.d. with ranitidine 300 mg
Number of subjects: 30
Study: 2129025

Group type: EXPERIMENTAL
Intervention: gliclazide
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: glibenclamide
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: glipizide
Number of subjects: 248
Study: 113370

Group type: EXPERIMENTAL
Intervention: Cream containing 5‐chloro‐8‐hydroxyquinoline, gentamycin and fluprednyliden‐21‐acetate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cream containing 5‐chloro‐8‐hydroxyquinoline and gentamycin alone
Number of subjects: 60
Study: 30888221

Group type: COMPARATOR
Intervention: Aerobic Training Group (ATG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Resistance Training Group (RTG)
Number of subjects: 34
Study: 29397376

Group type: EXPERIMENTAL
Intervention: semaglutide 0·5 mg
Number of subjects: 1201

Group type: COMPARATOR
Intervention: dulaglutide 0·75 mg
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: semaglutide 1·0 mg
Number of subjects: 1201

Group type: COMPARATOR
Intervention: dulaglutide 1·5 mg
Number of subjects: 1201
Study: 27055505

Group type: EXPERIMENTAL
Intervention: RFA, TACE, CIK
Number of subjects: 156

Group type: COMPARATOR
Intervention: RFA, TACE
Number of subjects: 156
Study: 24413350

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise training (HIT) - 3 hospital-based exercise sessions per week for 4 weeks, including 2 or 4 min of high-intensity stationary cycling followed by the same duration of easy cycling or passive recovery, repeated until a total of 16 min of high-intensity exercise is accumulated.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Post-operative outcomes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Quality of life assessment 12 weeks post-discharge
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Costs associated with the exercise intervention and healthcare utilisation
Number of subjects: 50
Study: 21833738

Group type: EXPERIMENTAL
Intervention: Injectable partly resorbable calcium sulfate (60 wt.%)/hydroxyapatite (40 wt.%) bone substitute
Number of subjects: 80
Study: 20849856

Group type: EXPERIMENTAL
Intervention: 1mg oral 17‐β estradiol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17351252

Group type: EXPERIMENTAL
Intervention: 3 cycles of BE500P
Number of subjects: 257

Group type: COMPARATOR
Intervention: 4 cycles of E500P
Number of subjects: 257
Study: 15765238

Group type: EXPERIMENTAL
Intervention: Living high-training low (LHTL) at simulated altitudes of 2,500, 3,000, and 3,500 m for 18 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group training and living at 1,200 m altitude
Number of subjects: 11
Study: 12478899

Group type: EXPERIMENTAL
Intervention: L-OHP plus HCPT
Number of subjects: 43

Group type: COMPARATOR
Intervention: VP-16 + CF + 5-FU (ELF)
Number of subjects: 43
Study: 9718224

Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific agents not detailed, but cyclophosphamide noted as most mutagenic)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 9
Study: 7917158

Group type: EXPERIMENTAL
Intervention: quinapril
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 2680226

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) administration in high UAER group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) administration in low UAER group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in high UAER group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in low UAER group
Number of subjects: 0
Study: 1112230

Group type: EXPERIMENTAL
Intervention: High-titre rubella immunoglobulin administered intramuscularly (20 ml)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no immunoglobulin)
Number of subjects: 56
Study: 7197091

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (gestagen therapy)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 31792258

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PEG‐LG) 40 mg/m2 plus cyclophosphamide (CPM) 600 mg/m2 followed by docetaxel (DTX) 85 mg/m2, administered in four cycles on a 21-day schedule.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PEG‐LG) plus cyclophosphamide (CPM) followed by docetaxel (DTX) regimen.
Number of subjects: 0
Study: 29492878

Group type: EXPERIMENTAL
Intervention: Fasiglifam
Number of subjects: 9139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9139

Group type: COMPARATOR
Intervention: Active Comparators (sitagliptin, glimepiride)
Number of subjects: 9139
Study: 27445610

Group type: EXPERIMENTAL
Intervention: Parasternal block
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 25002083

Group type: EXPERIMENTAL
Intervention: Intravenous propacetamol (1g IV dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral rizatriptan (5mg)
Number of subjects: 0
Study: 22542122

Group type: EXPERIMENTAL
Intervention: fesoterodine therapy (4-8 mg daily)
Number of subjects: 645

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 645
Study: 19054247

Group type: EXPERIMENTAL
Intervention: Angiographic group (RFA catheter selection based on CTI angiography)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Externally cooled-tip catheter group
Number of subjects: 119
Study: 17993029

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 18% carbamide peroxide whitening gel
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (fluoride toothpaste)
Number of subjects: 87
Study: 15679130

Group type: COMPARATOR
Intervention: etomidate 0.3 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: fentanyl 2 microg/kg and etomidate 0.3 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: succinylcholine 1 mg/kg and etomidate 0.3 mg/kg
Number of subjects: 60
Study: 12032266

Group type: EXPERIMENTAL
Intervention: Combination regimen (colestipol 5 g/d with pravastatin 10 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional regimen (colestipol 10 g/d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 36
Study: 9650540

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine therapy at 11 mg/day
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine therapy at 22 mg/day
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine therapy at 44 mg/day
Number of subjects: 70
Study: 7714284

Group type: EXPERIMENTAL
Intervention: Nursing care with a focus on emotional support
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Organizational changes in care (co-operation between surgical ward and primary health care, shorter waiting times, changed routines around information)
Number of subjects: 26
Study: 2716711

Group type: EXPERIMENTAL
Intervention: Jatrox (three times 2 tablets one hour before meals)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 15
Study: 1009064

Group type: EXPERIMENTAL
Intervention: 360 degrees scatter xenon photocoagulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 20
Study: 31859593

Group type: EXPERIMENTAL
Intervention: Cognitive biases (conjunction fallacy, sunk cost bias, information avoidance, present bias)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Information avoidance
Number of subjects: 1400
Study: 29908682

Group type: EXPERIMENTAL
Intervention: 3 g Melissa officinalis (MO) supplement daily for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26855550

Group type: EXPERIMENTAL
Intervention: CWI with 0.3% ropivacaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with 0.12% ropivacaine and 20 µg/mL morphine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia with 0.5 mg/mL morphine
Number of subjects: 75
Study: 24988100

Group type: EXPERIMENTAL
Intervention: Online mindfulness intervention (n = 44)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Wait-list control (n = 45)
Number of subjects: 89
Study: 22634446

Group type: EXPERIMENTAL
Intervention: 5 µg or 25 µg VLP immunotherapy
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 1 µg VLP immunotherapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo immunotherapy (0.9% NaCl)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo immunotherapy (0.9% NaCl) in Wenzhou
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: VLP immunotherapy in Wenzhou
Number of subjects: 85
Study: 19895362

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with birch pollen allergen extract
Number of subjects: 24
Study: 18565093

Group type: EXPERIMENTAL
Intervention: Menicon PremiO lenses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acuvue Oasys lenses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All lens/solution combinations
Number of subjects: 0
Study: 15882248

Group type: EXPERIMENTAL
Intervention: Probiotic therapy (Lactobacillus rhamnosus GG, L. rhamnosus LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp. shermanii JS) during H. pylori eradication and for 3 weeks following treatment.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo during H. pylori eradication and for 3 weeks following treatment.
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Probiotic therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 14659474

Group type: EXPERIMENTAL
Intervention: Buspirone (6 mg/kg in mice, 10 mg/kg in rats)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone (3 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone (10 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone (not specified dosage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic buspirone treatment (3 x 10 mg daily for 6 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social support from nonrelatives
Number of subjects: 0
Study: 10833209

Group type: EXPERIMENTAL
Intervention: Growth hormone (somatropin) - loading dose of 5 mg per day subcutaneously for one week, followed by a maintenance dose of 1.5 mg per day
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 8834888

Group type: EXPERIMENTAL
Intervention: Rufloxacin (400 mg, single dose)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Norfloxacin (400 mg twice a day for 3 days)
Number of subjects: 203
Study: 1557681

Group type: EXPERIMENTAL
Intervention: Family intervention combined with individual treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Individual treatment alone
Number of subjects: 75
Study: 3891615

Group type: EXPERIMENTAL
Intervention: Group I (n = 10) with maintained urinary sodium excretion at predieting level
Number of subjects: 18

Group type: COMPARATOR
Intervention: Group II (n = 8) with restricted energy and sodium intake
Number of subjects: 18
Study: 30148453

Group type: EXPERIMENTAL
Intervention: Bayesian approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional null hypothesis significance testing
Number of subjects: 0
Study: 27050325

Group type: EXPERIMENTAL
Intervention: Prehabilitation (one-hour twice-weekly sessions for at least three and a maximum of four weeks prior to surgery)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no pre-surgical programs)
Number of subjects: 64